Company / Operating Margin
ELITE PHARMACEUTICALS INC /NV/ Operating Margin History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
23.3%
FY2024
5-year range
10.8% / 23.3%
FY2020-FY2024
Trend
+22.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin has fluctuated over the past 9 years, ranging from -121.4% in FY2017 to 23.3% in FY2024.
Based on SEC 10-K filings.
23.3% in FY2024 with a 5-year CAGR of +36.0%.
Improved from 10.8% to 23.3% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- +7.6pp
- 5-Year Change
- +36.0pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, operating margin increased 22.4% year-over-year.
- Lowest operating margin in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | 23.3% | +22.4% |
| FY2023 | 19.1% | +77.0% |
| FY2022 | 10.8% | -31.6% |
| FY2021 | 15.7% | +89.6% |
| FY2020 | 8.3% | +165.3% |
| FY2019 | -12.7% | +89.5% |
| FY2018 | -121.0% | +0.3% |
| FY2017 | -121.4% | -59.0% |
| FY2016 | -76.3% | -14.7% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026